Jan 2, 11:00 AM

Poolbeg Pharma Shares Plummet 40% on January 2, 2025, Amid Acquisition Talks with Hookipa Pharma, Led by Cathal Friel

Poolbeg Pharma, a biopharmaceutical company based in Dublin, is in talks for a potential acquisition by Nasdaq-listed Hookipa Pharma. The announcement has led to a significant decline in Poolbeg's share price, which fell by 40% in London trading. The discussions for the acquisition were confirmed on January 2, 2025, amidst reports of a US tie-up led by Cathal Friel, the company's chairman. The news has drawn attention to the financial health of Poolbeg Pharma as the market reacts to the takeover talks.

#Poolbeg Pharma #Dublin #Nasdaq #Hookipa Pharma #Poolbeg #London #US #Cathal Friel

Written with ChatGPT (GPT-4o mini).

Sources

Business Post@businessposthq
2 years ago
Poolbeg Pharma, the Dublin-headquartered biopharmaceutical company, saw its share price plummet on Thursday as it announced it is in talks to be acquired by Nasdaq-listed Hookipa Pharma https://t.co/83SBHYpDyf
Markets Today@marketsday
2 years ago
Pool Corp. shares up 1.62% premarket after Nextchem's EUR125M credit line. $POOL
The Irish Times@IrishTimes
2 years ago
Cathal Friel-chaired Poolbeg Pharma in talks for US tie-up https://t.co/pA2kOMPriL

Poolbeg Pharma Shares Plummet 40% on January 2, 2025, Amid Acquisition Talks with Hookipa Pharma, Led by Cathal Friel

Sources

Additional media

Similar Stories